HYPR HYPR
Company Profile ↓Company Overview
HYPR (HYPR) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 115.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $13.56M (+5.2% YoY); net profit $-35.57M.
- Trailing 12 Months Year-on-year growth — revenue +5.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 115.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 115.18% |
| 1 Year: | 5.22% |
Stock Price Performance
| 1 Year: | -16.95% |
| 6 Months: | -13.27% |
| 3 Months: | -42.69% |
| 1 Month: | -19.67% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.61 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 115.2% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 55.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 331.00K | 358.00K | 371.00K | 1.51M | 1.53M | 2.35M | 2.63M | 3.38M | 2.33M | 3.29M | 3.63M | 3.64M | 2.14M | 2.70M | 3.44M | 3.90M |
| Gross Profit | -277.00K | -99.00K | -338.00K | 84.00K | -165.00K | 688.00K | 1.16M | 1.44M | 1.12M | 1.35M | 1.80M | 1.91M | 883.00K | 1.33M | 1.85M | 1.98M |
| Operating Income | -7.80M | -14.59M | -16.39M | -23.77M | -23.19M | -13.28M | -13.04M | -11.69M | -11.76M | -10.65M | -10.85M | -10.96M | -10.90M | -9.60M | -8.92M | -8.56M |
| Net Income | -7.79M | -14.58M | -16.39M | -23.77M | -23.16M | -13.17M | -12.16M | -10.64M | -10.76M | -9.85M | -10.16M | -10.33M | -9.42M | -9.22M | -11.02M | -8.62M |
| Diluted EPS | - | -8.80 | -8.66 | -0.34 | -0.33 | -0.19 | -0.17 | -0.15 | -0.15 | -0.14 | -0.14 | -0.14 | -0.12 | -0.12 | -0.14 | -0.09 |
| R&D Expense | 4.47M | 6.04M | 6.44M | 8.33M | 7.26M | 7.34M | 5.46M | 5.33M | 5.74M | 5.57M | 5.96M | 5.87M | 5.04M | 4.54M | 4.05M | 3.85M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 294.00K | 1.50M | 6.81M | 11.03M | 12.89M | 13.56M |
| Gross Profit | -477.00K | -1.17M | 907.00K | 4.76M | 5.89M | 6.75M |
| Operating Income | -23.49M | -64.87M | -73.87M | -48.12M | -43.22M | -37.09M |
| Net Income | -23.43M | -64.85M | -44.24M | -44.24M | -40.72M | -35.57M |
| Diluted EPS | - | -17.57 | -1.04 | -0.62 | -0.56 | -0.43 |
| R&D Expense | 14.59M | 25.84M | 28.16M | 22.49M | 22.50M | 17.45M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 71.53M | 202.47M | 134.05M | 94.20M | 58.90M | 55.26M |
| Total Equity | -39.86M | -61.05M | 186.23M | 123.72M | 84.40M | 49.04M | 41.01M |
| Cash & Equivalents | - | 62.68M | 188.50M | 117.47M | 75.18M | 37.65M | 35.09M |
| Total Liabilities | - | 4.29M | 16.25M | 10.33M | 9.80M | 9.86M | 14.26M |
| Current Liabilities | - | 4.12M | 15.74M | 8.80M | 8.77M | 8.73M | 11.73M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.52M | -47.18M | -72.34M | -41.81M | -38.77M | -27.95M |
| Investing Cash Flow | -1.57M | -2.71M | -585.00K | -804.00K | -383.00K | -1.19M |
| Financing Cash Flow | 60.94M | 176.77M | 7.00K | 174.00K | 1.02M | 27.50M |
| Capital Expenditure | -1.57M | -2.71M | -585.00K | -804.00K | -383.00K | -1.19M |
| Free Cash Flow | -23.09M | -49.89M | -72.92M | -42.61M | -39.15M | -29.13M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | -162.2% | -78.0% | 13.3% | 43.1% | 45.7% | 49.8% |
| Operating Margin % | -7,990.1% | -4,336.1% | -1,084.2% | -436.1% | -335.3% | -273.4% |
| Net Margin % | -7,968.4% | -4,335.0% | -649.2% | -401.0% | -315.9% | -262.3% |
| ROE % | 38.4% | -34.8% | -35.8% | -52.4% | -83.0% | -86.8% |
| ROCE % | -34.8% | -34.7% | -59.0% | -56.3% | -86.2% | -85.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HYPR
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates
RxSight (RXST) delivered earnings and revenue surprises of +47.62% and +2.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of +16.13% and +3.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Hyperfine Announces the Release of Multiple Peer-Reviewed Publications, Expanding Clinical Evidence for the Swoop® System Across a Growing Number of Sites of Care
GUILFORD, Conn., July 30, 2026--Multiple peer-reviewed publications in Journal of Neurosurgery and Stroke strengthen evidence for portable MRI in stroke and neurosurgical settings.
Hyperfine, Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026
GUILFORD, Conn., July 23, 2026--Hyperfine will report Q2 2026 financial results Thur., Aug. 6, 2026. Management will host a corresponding conference call at 1:30 PM PT/4:30 PM ET.
Hyperfine launches next-generation Swoop MRI system in Europe
The introduction of Model 2 into Europe aims to support Hyperfine’s international commercial objectives.
Hyperfine Announces European Launch of Next-Generation Swoop® System
GUILFORD, Conn., July 01, 2026--Hyperfine initiates the launch of the next-gen Swoop® system in Europe, beginning global expansion of its most advanced portable MRI technology.
HYPR — Frequently Asked Questions
What is the current share price of HYPR?
As of 2026-08-05 17:25 PDT, HYPR trades at $0.98 on NASDAQ/NYSE. Its 52-week range is $0.89 to $2.20.
What is the P/E ratio of HYPR?
HYPR trades at a trailing price-to-earnings (P/E) ratio of -2.28.
What is the return on equity (ROE) of HYPR?
HYPR has a return on equity (ROE) of -86.76%. Its return on capital employed (ROCE) is -85.19%.
Is HYPR a good stock to buy?
This page provides a data-driven analysis of HYPR, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.